10-Q: Revvity Q3 2025 Earnings: Revenue Up 2%, Margins Decline

Revvity, Inc. reported a 2% increase in Q3 2025 revenue to $698.9 million, though gross and operating margins decreased due to tariffs and unfavorable foreign exchange rates.

Summary

• Total revenue for the three months ended September 28, 2025, increased by 2% to $698.9 million, up from $684.0 million in the prior year period.
• Total revenue for the nine months ended September 28, 2025, increased by 3% to $2,084.0 million, up from $2,025.7 million in the prior year period.
• Net income for the three months ended September 28, 2025, was $46.7 million, a decrease from $94.4 million in the prior year period.
• Diluted earnings per share (EPS) for the three months ended September 28, 2025, was $0.40, down from $0.77 in the prior year period.
• Gross margin decreased by 266 basis points to 53.6% for the three months ended September 28, 2025, from 56.3% in the prior year, primarily due to increased tariffs, unfavorable foreign exchange rates, and product mix shift.
• Operating income from continuing operations for the three months ended September 28, 2025, was $81.9 million, a decrease from $98.2 million in the prior year period.
• Life Sciences segment revenue increased by 1% to $342.8 million in Q3 2025, driven by an $8.9 million increase in Software revenue, partially offset by a $4.9 million decrease in Life Sciences Solutions revenue.
• Diagnostics segment revenue increased by 3% to $356.1 million in Q3 2025, driven by a $9.7 million increase in Reproductive Health revenue and a $1.2 million increase in Immunodiagnostics revenue.
• Net cash provided by operating activities of continuing operations was $407.0 million for the nine months ended September 28, 2025, a decrease of $82.5 million from the prior year period, primarily due to timing of collections.
• The company repurchased 2,322,206 shares of common stock for an aggregate cost of $204.9 million during the three months ended September 28, 2025.
• A new $1.0 billion stock repurchase program was authorized on October 23, 2025, replacing the previous program.

Sentiment

Score: 4

Explanation: While revenue showed modest growth, significant declines in net income, EPS, and margins due to external factors like tariffs and unfavorable foreign exchange rates, coupled with a decrease in operating cash flow, indicate a challenging quarter. The new share repurchase program is a positive, but overall financial performance was weaker than the prior year.

Positives

• Total revenue increased by 2% for the three months and 3% for the nine months ended September 28, 2025, demonstrating continued top-line growth.
• Diagnostics segment revenue grew by 3% in Q3 2025, driven by strong performance in Reproductive Health and Immunodiagnostics.
• Life Sciences Software revenue showed robust growth, increasing by $8.9 million in Q3 2025 and $35.1 million for the nine months ended September 28, 2025.
• Selling, general and administrative expenses decreased as a percentage of revenue for both the three-month (34.6% vs 34.7%) and nine-month (35.5% vs 37.0%) periods, indicating effective cost controls and productivity gains.
• The company maintains a strong cash position with $931.4 million in cash and cash equivalents and $1.5 billion in available borrowing capacity under its senior unsecured revolving credit facility.
• A new $1.0 billion stock repurchase program was authorized, signaling management's confidence in future cash flow and commitment to shareholder returns.

Negatives

• Net income significantly decreased by 50.6% to $46.7 million in Q3 2025 from $94.4 million in Q3 2024.
• Diluted EPS decreased by 48.1% to $0.40 in Q3 2025 from $0.77 in Q3 2024.
• Gross margin decreased by 266 basis points to 53.6% in Q3 2025, primarily due to increased tariffs, unfavorable foreign exchange rates, and product mix shift.
• Consolidated operating margins decreased by 263 basis points in Q3 2025.
• Life Sciences Solutions revenue decreased by $4.9 million in Q3 2025 and $9.8 million for the nine months ended September 28, 2025.
• Interest income decreased significantly for both the three-month ($6.9 million vs $22.8 million) and nine-month ($25.4 million vs $63.4 million) periods due to a decrease in marketable securities and short-term investments.
• Net cash provided by operating activities of continuing operations decreased by $82.5 million for the nine months ended September 28, 2025, primarily due to timing of collections.
• The effective tax rate from continuing operations increased to 15.2% for Q3 2025 and 18.5% for the nine months ended September 28, 2025, compared to 6.9% and 12.1% in the prior year periods, primarily due to net favorable impacts of prior year true-ups recorded in fiscal year 2024 in foreign locations.
• Restructuring and other costs, net, increased to $9.9 million in Q3 2025 compared to a decrease of $0.1 million in Q3 2024.
• Transformation costs added an incremental expense of $5.1 million in Q3 2025 and $6.2 million for the nine months ended September 28, 2025.
• Significant litigation matters and settlements increased to $12.5 million for the nine months ended September 28, 2025, from $7.1 million in the prior year period.

Risks

• Declines in general economic conditions, uncertainties in government or industrial funding proposals, or unfavorable changes in government regulations could adversely affect business operations, demand for products, and pricing pressures.
• Global economic and political conditions, including inflation, recession, financial liquidity, interest rates, currency volatility, trade protectionism, tariffs, and geopolitical conflicts, could interfere with the supply chain, customers, and overall activities.
• Failure to introduce new products in a timely manner could lead to loss of market share and inability to achieve revenue growth targets in rapidly changing industries.
• Inability to successfully execute acquisitions or divestitures, license technologies, integrate acquired businesses, or make them profitable.
• Aggressive competition from numerous competitors with significant financial resources, intellectual property portfolios, and established distribution channels.
• Significant fluctuations in quarterly operating results due to demand, competitive pressures, economic activity, trade policy, government funding, tax audits, environmental claims, litigation, raw material costs, and foreign currency exchange rates.
• Significant disruption in third-party package delivery and import/export services, or significant price increases for these services, could interfere with product shipments, increase costs, and lower profitability.
• Disruptions in the supply of raw materials, key components, and other goods from limited or single-source suppliers could have an adverse effect on business operations and customer relationships.
• Inability to retain key personnel (executive officers, management, technical personnel) or successfully execute leadership succession plans.
• Significant disruption in, or breach of security of, information technology systems (including cybercrime) of the company or third parties, or failure to implement new systems, could adversely affect business, lead to asset loss/misappropriation, or unauthorized disclosure of confidential information.
• Failure to realize the full value of intangible assets (goodwill, patents, trademarks, customer relationships, core technology) could result in impairment charges, adversely affecting results of operations.
• Inadequate protection of intellectual property (patents, trade secrets, trademarks) or challenges to their validity/infringement claims.
• Inability to renew licenses or loss of licensed rights, potentially requiring cessation of product sales or loss of competitive advantage.
• Exposure to product and other liability claims for which insurance may be inadequate.
• Failure to maintain satisfactory compliance with regulations of the United States Food and Drug Administration and other governmental agencies, leading to recalls, manufacturing cessation, or civil/criminal penalties.
• Stringent data privacy and information security laws and regulations, with non-compliance leading to significant fines and penalties.
• Changes in governmental regulations (environmental, health and safety, data privacy, food and drug) reducing demand or increasing expenses.
• Failure to comply with extensive healthcare industry laws and regulations, leading to fines, penalties, or operational changes.
• Economic, political, and other risks associated with foreign operations (currency exchange rates, global health crises, wars, trade protection measures, import/export restrictions, differing tax laws, difficulty transferring cash, differing labor laws, intellectual property protection, data protection, anti-bribery laws).
• Substantial outstanding debt impacting ability to obtain future financing and limiting other expenditures, exposing to interest rate and foreign currency risk, and increasing downgrade chances.
• Restrictive covenants in debt instruments limiting activities such as dividend payments, asset sales, and incurring obligations.
• Share price fluctuation due to operating results, market performance, strategic announcements, global financial markets, and economic conditions.
• Potential reduction or elimination of common stock dividends in the future to fund investments, share repurchases, or conserve capital.

Future Outlook

The effective tax rate on continuing operations, before discrete items, is expected to be approximately 20% during fiscal year 2025. The recently enacted One Big Beautiful Bill Act (OBBBA) in the U.S. is not expected to materially impact the fiscal year 2025 provision for income taxes, but the company will continue to evaluate its full impact as additional guidance becomes available. The company expects to repay the 1.875% Senior Unsecured Notes due in 2026 with existing cash on hand or drawings from its senior unsecured revolving credit facility, or a combination thereof. The Board may determine to reduce or eliminate the common stock dividend in the future to fund investments for growth, repurchase shares, or conserve capital resources. Tariffs recently enacted and currently in effect could increase cost of revenue for the current fiscal year by approximately $25 million, but mitigating actions are anticipated to result in a decrease to gross margin of approximately $20 million.

Management Comments

• Our overall revenue in the third quarter of fiscal year 2025 was $698.9 million which increased by $14.9 million, or 2%, as compared to the third quarter of fiscal year 2024, reflecting an increase of $10.9 million, or 3%, in our Diagnostics segment revenue, and an increase of $4.0 million, or 1%, in our Life Sciences segment revenue.
• The increase in our Diagnostics segment revenue for the third quarter of fiscal year 2025 was driven primarily by our Reproductive Health business.
• The increase in our Life Sciences segment revenue for the third quarter of fiscal year 2025 was driven by increased revenue in our Software business.
• Our consolidated gross margins decreased 266 basis points in the third quarter of fiscal year 2025, as compared to the third quarter of fiscal year 2024, primarily due to increased tariffs, unfavorable changes in foreign exchange rates, and product mix shift.
• Our consolidated operating margins decreased 263 basis points in the third quarter of fiscal year 2025, as compared to the third quarter of fiscal year 2024, due to gross margin headwinds as discussed above.
• We now estimate that pursuant to the tariffs recently enacted and currently in effect, our cost of revenue for the current fiscal year could increase by approximately $25 million. However, we anticipate that as the result of the mitigating actions that we have taken and plan to take, the tariffs would result in a decrease to our gross margin for the current fiscal year of approximately $20 million.
• We are implementing a comprehensive mitigation strategy that includes manufacturing optimization, supplier collaboration, selective pricing actions, and targeted temporary cost measures to minimize financial exposure.
• We anticipate that our internal operations will generate sufficient cash to fund our operating expenses, capital expenditures, acquisitions, interest payments on our debt and dividends on our common stock, for the foreseeable future, including at least the next 12 months.

Industry Context

Revvity operates in the health science solutions industry, providing technologies and services from discovery to diagnosis. The company's performance reflects a mixed environment, with modest revenue growth driven by its Diagnostics segment (particularly Reproductive Health) and Life Sciences Software, but facing significant headwinds from global economic factors such as increased tariffs and unfavorable foreign exchange rates, which impacted gross and operating margins. The company's strategic focus on 'translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics' aligns with high-growth and innovation-driven areas within the broader healthcare and life sciences sectors. The impact of the recently enacted 'One Big Beautiful Bill Act' in the U.S. highlights the ongoing influence of evolving tax policy on corporate financial planning and operations.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The company is subject to various claims, legal proceedings, and investigations covering a wide range of matters that arise in the ordinary course of its business activities, including product liability claims.
• Accruals for potential losses are established when the company's responsibility is probable and the cost can be reasonably estimated.
• Management believes that the total cost of resolving these contingencies at September 28, 2025, should not have a material adverse effect on the condensed consolidated financial statements.
• The company is conducting environmental investigations and remedial actions at current and former locations, with an accrued amount of $11.1 million as of September 28, 2025, for remediation costs, expected to be paid out over up to ten years.

Stakeholder Impact

• Shareholders are impacted by decreased net income and EPS, but benefit from the authorization of a new $1.0 billion stock repurchase program and continued quarterly dividends of $0.07 per share, though future dividend reductions are possible.
• Employees may be impacted by restructuring and other costs, and transformation initiatives, with retention of key personnel identified as a risk factor.
• Customers may experience reduced demand for products and services due to general economic conditions, funding uncertainties, or regulatory changes, and could face supply chain disruptions.
• Suppliers face potential disruptions in the supply of raw materials and components, especially from limited or single sources, which could affect their relationship with the company.
• Creditors are affected by the company's debt levels and restrictive covenants in debt instruments, though the company expects to repay maturing notes and has a new revolving credit facility.

Next Steps

• Repay the 1.875% Senior Unsecured Notes due in 2026 in July 2026 using existing cash or the senior unsecured revolving credit facility, or a combination thereof.
• Continue implementing a comprehensive mitigation strategy for tariffs, including manufacturing optimization, supplier collaboration, selective pricing actions, and targeted temporary cost measures.
• Evaluate the full impact of the One Big Beautiful Bill Act (OBBBA) as additional guidance becomes available.
• The Board will continue to declare quarterly dividends, with the next one for Q4 2025 payable in February 2026.
• Continue repurchasing shares under the New Repurchase Program, which expires on October 22, 2027.
• Perform the annual goodwill impairment testing on November 3, 2025.

Key Dates

Recommendation

While Revvity demonstrated modest revenue growth in Q3 2025, the significant decline in net income and EPS, coupled with margin compression due to external factors like tariffs and unfavorable foreign exchange rates, presents a mixed financial picture. The company's strong cash position and new share repurchase program offer some support and signal confidence, but ongoing operational headwinds, increased restructuring, transformation costs, and litigation expenses warrant caution. Investors should monitor the effectiveness of mitigation strategies against tariffs and the broader impact of global economic conditions on the company's profitability and cash flow. The current environment suggests a 'hold' stance until there is clearer evidence of margin stabilization and improved earnings trajectory.

Keywords

Life Sciences, Diagnostics, Reproductive Health, Immunodiagnostics, Software, SEC Filing, 10-Q, Financial Results, Revenue, Net Income, EPS, Gross Margin, Operating Income, Cash Flow, Stock Repurchase, Tariffs, Foreign Exchange, Risk Factors, Healthcare Solutions, Biotechnology, Pharmaceutical, Corporate Governance, Debt, Shareholder Returns